MedImmune Sponsors Cancer Research Fellowship to Support Development of Biologics-Based Cancer Therapies

Strategic Insights -

MedImmune, Inc., a global biotechnology company, has sponsored an American Association for Cancer Research (AACR) fellowship to support the development of biologics-based cancer therapies. The recipient of the $40,000 research fellowship, Robert R. Jenq, MD, of the Memorial Sloan-Kettering Cancer Center in New York, is evaluating several techniques to enhance T-cell response and recovery following bone marrow transplantation, aiming to augment tumor-specific immunity and potentially increase tumor-free survival. This research builds on previous preclinical studies conducted in murine models of malignant melanoma, suggesting that DNA vaccination may lead to increased T-cell responses and improved tumor-free survival. MedImmune has invested heavily in cancer research, with over $2 billion in research funds invested to date.

Key Takeaways:

  • MedImmune has sponsored a $40,000 research fellowship to support the development of biologics-based cancer therapies through the American Association for Cancer Research (AACR).
  • Robert R. Jenq, MD, a medical oncology fellow at the Memorial Sloan-Kettering Cancer Center, is the recipient of the fellowship, which aims to enhance T-cell response and recovery after bone marrow transplantation.
  • The research focuses on evaluating several techniques to augment tumor-specific immunity and potentially increase tumor-free survival.
  • The study builds on previous preclinical research conducted in murine models of malignant melanoma, suggesting the potential of DNA vaccination in increasing T-cell responses and improving tumor-free survival.
  • MedImmune has invested over $2 billion in research funds to develop new and next-generation medicines, with 11 product candidates in its oncology pipeline, six of which are in clinical development.
  • The company is focused on areas such as infectious diseases, cancer, and inflammatory diseases.
  • The American Association for Cancer Research is a professional organization dedicated to preventing and curing cancer, with a mission to advance cancer research and a vision to create a world free from cancer.

Statistics:

  • MedImmune has invested over $2 billion in research funds to develop new and next-generation medicines.
  • 11 product candidates in MedImmune's oncology pipeline, with six of them in clinical development.
  • $40,000 research fellowship sponsored by MedImmune through the American Association for Cancer Research (AACR).
  • Over 15 investigators, including Robert R. Jenq, MD, selected by the AACR to receive a grant this year.
  • Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research.

Sources:

  • [MedImmune Sponsors Cancer Research Fellowship, American Association for Cancer Research (AACR), 97th Annual Meeting, Washington, DC]
  • [World Disease Weekly editors, Copyright 2006, World Disease Weekly via NewsRx.com]